GlassScriptPhysician profile
Ellsworth R Grant
NPI 1043233760
$22,206.40
in general payments reported to CMS, 2019-2025
76 companies · $4,118 in 2025
The $4,118 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,173 · 2020: $1,724 · 2021: $2,752 · 2022: $3,820 · 2023: $3,881 · 2024: $3,740 · 2025: $4,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,355 · Long Term Medical Supply Or Device Loan: $2,283 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,355.33 |
| Long Term Medical Supply Or Device Loan | $2,282.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,304.24 | 2019-2025 | |
| Pfizer INC. | $1,559.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,470.99 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $1,164.34 | 2019-2025 | Erleada, Darzalex, Akeega |
| Genentech USA, INC. | $879.54 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Merck Sharp & Dohme LLC | $872.42 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $783.76 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $780.45 | 2019-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $775.84 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Astellas Pharma US INC | $696.51 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Exelixis INC. | $682.29 | 2019-2025 | Cabometyx |
| Amgen INC. | $634.78 | 2019-2023 | Lumakras, Kyprolis, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $582.20 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genzyme Corporation | $560.48 | 2019-2025 | |
| Eisai INC. | $430.21 | 2019-2024 | Lenvima |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellsworth Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.